Author:
Yao Sun,Na Liu,Liangding Hu
Funder
the National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544
2. Shomali W, Gotlib J (2022) World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(1):129–148. https://doi.org/10.1002/ajh.26352
3. Steven H, Elias S, Nancy C, Elaine LH, Stefano SJ, Harald AP, Jurgen S (2017) T WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th Edition 2
4. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, Prümmer O, Rauh S, Hehlmann R, Hochhaus A, Cross NC, Reiter A (2007) Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92(2):163–169. https://doi.org/10.3324/haematol.10980
5. Asnafi AA, Deris Zayeri Z, Shahrabi S, Zibara K, Vosughi T (2019) Chronic myeloid leukemia with complex karyotypes: prognosis and therapeutic approaches. J Cell Physiol 234(5):5798–5806. https://doi.org/10.1002/jcp.27505